Integra LifeSciences Holdings Corporation
IARTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeIntegra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and. With a market capitalization of $1.25B, it sits in small-cap territory. It operates through Codman Specialty Surgical and Tissue Technologies segments.
Market Cap
$1.25B
Beta
1.08
P/E (TTM)
—
P/E (Fwd)
6.14
EPS (TTM)
$-6.47
EPS (Fwd)
$2.61
ROE
-38.6%
ROA
2.5%
Cash
$265.5M
Total Debt
$2.04B
Free CF
$69.3M
52W Change
30.2%
Annual Financials
Cash vs Debt
The company holds $265.5M in cash, though total debt stands at $2.04B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $69.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -38.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.5% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $1.56B (2022) to $1.64B (2025).
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IART.